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The histone acetyltransferase (HAT) p300/CBP is a
transcriptional coactivator implicated in many gene
regulatory pathways and protein acetylation events.
Although p300 inhibitors have been reported, a
potent, selective, and readily available active-site-
directed small molecule inhibitor is not yet known.
Here we use a structure-based, in silico screening
approach to identify a commercially available pyra-
zolone-containing small molecule p300 HAT inhib-
itor, C646. C646 is a competitive p300 inhibitor with
a Ki of 400 nM and is selective versus other acetyl-
transferases. Studies on site-directed p300 HAT
mutants and synthetic modifications of C646 confirm
the importance of predicted interactions in confer-
ring potency. Inhibition of histone acetylation and
cell growth by C646 in cells validate its utility as a
pharmacologic probe and suggest that p300/CBP
HAT is a worthy anticancer target.
INTRODUCTION
The reversible acetylation of histones and other proteins rivals
protein phosphorylation as a major mechanism for cellular regu-
lation (Walsh, 2006; Choudhary et al., 2009; Macek et al., 2009).
Acetylation on protein lysine residues is catalyzed by histone
acetyltransferases (HATs) and acetyl-Lys cleavage is performed
by histone deacetylases (HDACs) (Hodawadekar and Marmor-
stein, 2007; Haberland et al., 2009; Cole, 2008). These enzymes
and the associated acetylation events have been implicated in
a wide variety of physiological and disease processes. In this
study, we focus on the paralog HATs p300 and CBP (referred
to as p300/CBP), which were originally discovered as E1A onco-Chemistry & Biology 17,protein binding partners and cyclic AMP effectors, respectively
(Goodman and Smolik, 2000). p300/CBP often serves as a
transcriptional coactivator and has been suggested to bind to
a range of important transcription factors (Goodman and Smolik,
2000). In 1996, p300/CBP was reported to possess intrinsic HAT
activity (Ogryzko et al., 1996; Bannister and Kouzarides, 1996).
Over the ensuing years, p300/CBP has been shown to be a rather
promiscuous acetyltransferase, with more than 75 protein
substrates described including p53, MyoD, and NFkB (Gu and
Roeder, 1997; Yang et al., 2008; Wang et al., 2008). Dissecting
the importance of the enzymatic activity of p300/CBP as
opposed to its protein recruitment functions in clarifying p300/
CBP’s biological roles would benefit from selective cell-perme-
able HAT inhibitors. Recent studies suggest that the biologic
functions of p300/CBP HAT activity may be associated with
tumorigenesis, and it is therefore plausible that p300/CBP HAT
inhibitors may serve as potential anticancer agents (Dekker
and Haisma, 2009; Iyer et al., 2007).
Although studies on histone deacetylases have led to the
discovery of highly potent compounds with clinical impact in
cancer, the identification of histone acetyltransferase inhibitors
has proved more challenging (Cole, 2008). Several reports of
p300/CBP HAT inhibitors identified through screens or based
on bisubstrate analogs have been published (Lau et al., 2000b;
Thompson et al., 2001; Zheng et al., 2005; Guidez et al., 2005;
Liu et al., 2008a; Stimson et al., 2005; Balasubramanyam et al.,
2003; Balasubramanyam et al., 2004; Mantelingu et al., 2007;
Arif et al., 2009; Ravindra et al., 2009). The most potent and selec-
tive compound, Lys-CoA (Ki = 20 nM), has been converted to
a cell-permeable form with Tat peptide attachment (Lys-CoA-
Tat) and has been used in a variety of studies, but its complexity
is somewhat limiting for pharmacologic applications (Lau et al.,
2000a; Thompson et al., 2001; Zheng et al., 2005; Guidez et al.,
2005; Liu et al., 2008b). High-throughput screening experiments
have led to several small molecule synthetic agents and natural
product derivatives of moderate potency as p300 HAT inhibitors471–482, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 471
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p300/CBP HAT Inhibition(micromolar Ki values), but their selectivity and mechanism of
inhibition remain to be fully characterized (Stimson et al., 2005;
Balasubramanyam et al., 2003; Balasubramanyam et al., 2004;
Mantelingu et al., 2007; Arif et al., 2009; Ravindra et al., 2009).
A recent high-resolution X-ray structure of the p300 HAT in
complex with the bisubstrate analog Lys-CoA has revealed key
aspects of substrate recognition and catalytic mechanism (Liu
et al., 2008a). A narrow tunnel in p300 accommodates Lys-
CoA, and the inhibitor makes a range of hydrogen bonding and
Van der Waals interactions with the HAT active site (Liu et al.,
2008a). Based on this structure and steady-state kinetic studies,
a Theorell-Chance catalytic mechanism has been proposed (Liu
et al., 2008a). This ‘‘hit and run’’ kinetic mechanism involves
initial, stable binding of acetyl-CoA followed by weak and tran-
sient interaction with histone substrate, which permits acetyl
transfer. The p300/CBP mechanism differs from that of another
family of HATs, PCAF/GCN5 (Poux et al., 2002), which use
a ternary complex mechanism.
The p300 HAT/Lys-CoA crystal structure affords the opportu-
nity for computational docking of novel inhibitory scaffolds. In
this regard, recent virtual ligand screening based on the X-ray
structure of serotonin N-acetyltransferase (AANAT) complexed
to a bisubstrate analog led to the identification of a novel, moder-
ately potent and selective small molecule inhibitor for this circa-
dian rhythm enzyme (Szewczuk et al., 2007). In this study, we
have pursued the use of this Lys-CoA/p300 HAT structure in
virtual ligand screening to identify novel small molecule p300
HAT inhibitors. Below, we describe an in silico search and exper-
imental validation that has led to a commercially available, selec-
tive, submicromolar small molecule p300 HAT inhibitory agent
with pharmacologic potential.
RESULTS
Ranking and Selection of Compounds from Virtual
Screening of the p300 HAT
Compounds from a screening set of nearly 500,000 commer-
cially available small molecules were docked into the p300
HAT structure in the Lys-CoA binding pocket and assigned
a score using the ICM-VLS software version 3.5. The compo-
nents of the ICM (internal coordinate mechanics) score include
the internal force-field energy of the ligand, conformational
entropy loss of the ligand, receptor-ligand hydrogen-bond inter-
action, solvation electrostatic energy change, hydrogen-bond
donor/acceptor desolvation, and hydrophobic energy (Totrov
et al., 1999). The score is trained to separate binders and non-
binders and to rank the interaction of the compound with the
receptor. The best score from each of the three docking runs
was recorded. The screened compounds were then ranked by
ICM score and the 194 highest-scoring compounds (represent-
ing 0.04% of the total compound database) were visually
inspected and selected based on their availability and interac-
tions with the receptor. Each of the 194 compounds was
purchased from ChemBridge and tested experimentally as
described below.
Experimental p300 HAT Assays and Inhibitor Validation
After completing the computational docking screen, we tested
the top 194 inhibitors of the p300 HAT by employing a convenient472 Chemistry & Biology 17, 471–482, May 28, 2010 ª2010 Elsevierspectrophotometric assay (Kim et al., 2000) followed by a series
of secondary assays (see Table S1 available online). In the
coupled spectrophotometric assay, the acetyltransferase reac-
tion product CoASH becomes a substrate for alpha-ketogluta-
rate dehydrogenase, which converts NAD to NADH, resulting
in an increase of UV absorbance at 340 nm (Kim et al., 2000).
Screening conditions for these p300 assays included semisyn-
thetic HAT enzyme (Thompson et al., 2004), substrate concen-
trations of 200 mM histone H4-15 peptide and 50 mM acetyl-
CoA, and potential small molecule inhibitors tested at 100 mM.
Thirty of the original 194 compounds showed at least 50% inhi-
bition under these conditions. To distinguish inhibitory effects
related to blockade of coupling enzyme rather than p300, assays
were repeated using increased (2-fold) alpha-ketoglutarate
dehydrogenase. This eliminated 6 of the 30 hits. To test for
protein aggregation-related inhibitory phenomena (Feng et al.,
2005), assays with the remaining compounds were next per-
formed in the presence of 0.01% Triton X-100, which attenu-
ated inhibition of eleven of 24 compounds. Nuclear magnetic
resonance (NMR) and mass spectrometry confirmed the struc-
ture and purity of the 13 potential p300 inhibitors that were
subsequently tested in a direct, radioactive assay for IC50
measurements. In this radioactive p300 HAT assay, 14C transfer
from 14C-acetyl-CoA into peptide substrate is directly measured
using Tris-Tricine SDSPAGE and phosphorimage analysis.
Three compounds, C646 (ChemBridge#5838646), C146 (Chem-
Bridge#5202146), and C375 (ChemBridge#6643375), were ulti-
mately shown to be relatively potent p300 HAT inhibitors
(Ki < 5 mM) (Figure 1A). Interestingly, though C646, C146, and
C375 possess distinct scaffolds, these three compounds all
contain a linear arrangement of three or four aromatic rings
terminating in a benzoic acid.
Acetyltransferase Inhibitor Selectivity
Each of the three inhibitors, C646, C146, and C375, was fur-
ther analyzed versus other acetyltransferases for specificity
(Table S2). We looked at serotonin N-acetyltransferase (Szewc-
zuk et al., 2007), PCAF histone acetyltransferase (Lau et al.,
2000a), GCN5 histone acetyltransferase (Poux et al., 2002),
Rtt109 histone acetyltransferase (Tang et al., 2008), Sas histone
acetyltransferase (Shia et al., 2005), and MOZ histone acetyl-
transferase (Holbert et al., 2007). Although compound C646 at
10 mM was highly selective in inhibiting p300 (86% inhibition)
versus the other six acetyltransferases (less than 10% inhibition),
C146 and C375 were less selective, inhibiting at least one of
these enzymes with comparable potency to their p300 blockade
(Table S2). Thus, compound C646 looked most promising for
applications requiring selective inhibition of p300/CBP.
Mechanism of p300 Inhibition
We evaluated the steady-state kinetic mechanism of inhibition
of p300 by compounds C646, C146, and C375 by exploring
inhibitory effects over a range of acetyl-CoA concentrations.
Compounds C646 proved to be a linear competitive inhibitor
of p300 versus acetyl-CoA with a Ki of 400 nM (Figure 1B).
Compound C146 showed pseudocompetitive inhibition versus
acetyl-CoA with Ki-slope = 4.7 mM, although this compound
exhibited a measurable Ki-intercept (35 mM), suggesting that
C146 still had affinity for the acetyl-CoA-bound form of p300Ltd All rights reserved
Figure 1. Small Molecule p300/CBP HAT Inhibition and C646
Analysis
(A) Three validated p300 HAT small molecule inhibitors C646, C375, and C146
and their inhibitory constants measured as described in B and Figure S1.
(B) Inhibitory characteristics of C646 toward p300. (A) Plot of 1/v versus
1/[acetyl-CoA] at fixed H4-15 peptide substrate (100 mM) and three concentra-
tions of C646 shows competitive inhibition. C646 Ki = 400 ± 60 nM, apparent
acetyl-CoA Km = 8.5 ± 1.4 mM, apparent kcat = 18 ± 1 min
-1.
(C) Plot of 1/v versus 1/[peptide substrate (H4-15)] at fixed acetyl-CoA (10 mM)
and three concentrations of C646 shows noncompetitive inhibition. C646
Ki = 530 ± 40 nM, apparent H4-15 Km = 155 ± 19 mM, apparent
kcat = 40 ± 2 min
-1.
Chemistry & Biology
p300/CBP HAT Inhibition(Figure S1A) (Copeland, 2000). C375 showed classical noncom-
petitive inhibition versus p300 (Ki = 4.8 mM), indicating that it
could bind efficiently to the acetyl-CoA bound form of p300
(Figure S1B). Computational models of the complex of these
compounds bound to p300 show extensive overlap with the
CoA-p300 interaction, so we predicted that a pure competitive
kinetic model would be observed. This was only true for C646.
In further analysis, compound C646 showed a noncompetitive
pattern of p300 inhibition versus H4-15 peptide substrate
(Figure 1C), consistent with the expected behavior of a bisub-
strate analog interacting with an enzyme with ordered substrate
binding, like that of p300 (Yu et al., 2006). Compound C146 wasChemistry & Biology 17,found to be a competitive inhibitor of p300 versus H4-15 peptide
substrate (Figure S1C), suggesting a more complex mode of
interaction with the enzyme than a simple bisubstrate analog.
C646 Is Not a Time-Dependent Inactivator of p300
The conjugated pyrazolone exomethylene vinyl functionality in
C646 appeared to us to be potentially electrophilic, serving as
a possible Michael acceptor, which could covalently modify its
protein target. The nucleophilic compound dithiothreitol (DTT)
was added to p300 HAT assays, and we showed that C646
inhibitory potency was similar (within 2-fold) if DTT was replaced
with beta-mercaptoethanol or glutathione. We investigated
whether DTT or beta-mercaptoethanol could generate adducts
with C646, however NMR and chromatography revealed no
evidence of reaction under the buffer conditions of the enzyme
assay. We deduce that this resistance to thiol adduct formation
results from the extended conjugation of the polyaromatic
system in C646.
Irreversible enzyme inhibitors typically exhibit time-dependent
enzyme inactivation (Copeland, 2000; Kitz and Wilson, 1962).
In contrast, acetyl transfer catalyzed by p300 HAT in the pres-
ence of C646 remained linear over time, consistent with the
behavior of a reversible inhibitor (Figure S2A). Moreover, incuba-
tion of C646 with p300 for 2, 4, 6, 8, or 10 min prior to acetyltrans-
ferase assays showed that the level of inhibition was independent
of preincubation time (Figure S2B). Taken together, these results
suggest that C646 is a classical reversible p300 inhibitor, consis-
tent with the steady-state kinetic analysis described above.
Conformational Analysis of C646
Prior studies suggested that pyrazolone-furan compounds such
as C646 could exist in two double bond stereoisomers involving
the exomethylene (Moreau et al., 2008) (Figure S3A). Because
the computational docking model of C646 bound to p300 sug-
gests that the compound binds as the Z-isomer, we investigated
C646 stereochemistry in solution using 1H NMR and high-pres-
sure liquid chromatography (HPLC). 1H NMR analysis of C646
in dimethyl sulfoxide (DMSO) suggests a 70:30 Z:E-mixture of
the olefinic isomers based on the pyrazolone methyl protons
(Figure S3A). Using 1H-1H 2D nuclear Overhauser enhancement
spectroscopy (NOESY), the major peak can be assigned as the
Z-isomer based on the NOE between the vinyl proton and methyl
protons in the Z-isomer.
We also show that these isomers can be separated by reverse-
phase HPLC (Figure S3B) but that they facilely interconvert,
since re-injection of samples derived from the individual peaks
shows that re-equilibration of peaks is established within a few
hours. These data suggest that the Z-isomer is readily accessible
and likely to be favored in solution.
Exploring the Interactions of C646 and p300
Using Site-Directed Mutagenesis
While we have not yet been successful in obtaining an X-ray
structure of C646 complexed to p300 HAT, we have used site-
directed mutagenesis to evaluate specific interactions predicted
by the computational model. In this model, a series of hydrogen
bonding donor interactions from the side chains of Thr1411,
Tyr1467, Trp1466, and Arg1410 to oxygen atoms of C646 are
proposed (Figure 2A). These side chains also make interactions471–482, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 473
Figure 2. Interactions of C646 with p300
(A) In silico model of C646 bound to p300 HAT active site (upper) shows over-
lapping interactions with the X-ray crystal structure of p300 HAT complexed
with Lys-CoA (lower).
(B) Kinetic analysis of selected active site mutants.
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p300/CBP HAT Inhibitionwith Lys-CoA based on the X-ray structure (Figure 2A) (Liu et al.,
2008a). We thus tested C646 against p300 HAT mutants
T1411A, Y1467F, W1466F, and R1410A and the corresponding
IC50 values are shown in Figure 2B. Because each of these
mutants can alter acetyl-CoA interactions as well, we measured
the corresponding Kms for acetyl-CoA for the four mutant474 Chemistry & Biology 17, 471–482, May 28, 2010 ª2010 Elsevierproteins and used the equation Ki = IC50/(S/Km+1) to calculate
the apparent Ki values based on a competitive inhibition model
(Copeland, 2000). As shown in Figure 2B, each mutation
increased the apparent Ki of C646 by at least 2-fold, and the
most significant effect was seen with W1466F, which showed
a 7-fold increase in Ki. This increase may reflect a combination
of the loss of the hydrogen bond from the indole nitrogen as
well as altered van der Waals contacts. It is noteworthy that
the kcat/Km for W1466F p300 is essentially identical to the wild-
type enzyme (Figure 2C), suggesting that inhibition by C646
and catalysis rely on subtly different forces.Structure-Activity Relationship Analysis of C646
in p300 Inhibition
To explore structural elements of C646 responsible for inhibition
of p300, we developed modular synthetic approaches to a series
of analogs that could probe the benzoate, pyrazolone, exo-
methylene, and arylnitro moieties (see Figure 3; Supplementary
Schemes 1-9). The general synthetic approach to prepare many
of these analogs involved initially producing the building block
phenyl-pyrazolones (3) and the aryl-furan aldehydes (Figure 3).
Production of the phenyl-pyrazolones (3) (Kim and Lee, 1991)
was achieved from the corresponding anilines 1, which could
be diazotized and transformed to the aryl hydrazines (2). Reac-
tion of intermediates 2 with ethyl acetylacetate led to pyrazo-
lones (3) formation. Palladium-catalyzed Suzuki coupling of
5-formyl-2-furanboronic acid with aryl halides (4) led to aryl-furan
aldehydes (5) (Langner et al., 2005; Hosoya et al., 2003). Knoeve-
nagel condensation between 3 and 5 generated the desired
analogs of C646 (Vasyunkina et al., 2005).
Each of the analogs 6a-r along with two other related commer-
cially available derivatives were tested for p300 HAT inhibition
using the direct, 14C-acetyl-CoA transfer assay at a range of
concentrations and the relative IC50s are shown in Figure 4.
Derivatization of the carboxylic acid of C646 as the methyl ester
affording 6h led to a dramatic weakening of inhibitory potency
(>15-fold), establishing the likely importance of this functionality
in hydrogen bonding. Reduction of the C646 enone with sodium
borohydride gives rise to C37 (6c) and this compound did not
detectably block p300 HAT activity (Figure 4). The loss of inhib-
itory potency of C37 suggests that shape (planarity) and/or elec-
tronic properties of the conjugated system in C646 is critical.
Replacement of the C646 nitro group with hydroxymethyleneFigure 3. Synthetic Approach to Many of
the C646 Analogs in Figure 4
More detailed synthetic schemes are shown in the
Supplemental Information (Schemes S1-S9).
Ltd All rights reserved
Figure 4. Synthetic Analogs of C646 and
Their Relative IC50s for p300 Inhibition
Referenced to C646
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p300/CBP HAT Inhibition(6l) also led to a substantial reduction in potency, supporting the
importance of hydrogen bonding of the nitro predicted by the
computational model.
Other hydrogen bond acceptors replacing the C646 para-
carboxylic acid were well tolerated at both the para and meta
positions including a para-carboxamide (6a), a para-sulfonic
acid (6f), a para-sulfonamide (6g), and a meta-methyl ester (6i)
or carboxylic acid (6e). Molecular modeling reveals consider-
able p300 active-site flexibility in accommodating these other
para- and meta-substituted compounds (Figure S4). Molecular
recognition versatility with regard to nitrophenyl interactions is
indicated by the fact that replacement of the nitro group by meth-
ylbenzoate (6m) or cyanophenyl (6o) functionalities is also well
tolerated (Figure 4). That the nitrophenyl group could be
effectively replaced by a methylbenzoate might offer pharmaco-Chemistry & Biology 17, 471–482, May 28, 2010kinetic advantages for in vivo studies
(Hodgkiss et al., 1991). However, replace-
ment of the nitrophenyl ring with a pyri-
dine ring (6p) eliminated p300 inhibitory
action.
Replacing the pyrazolone of C646 with
a succinimide ring in the context of a
methyl benzoate substituent replacing
the nitro group (6r) retains potency for
p300 inhibition (Figure 4). We have found
that a propionate group (6k) cannot
successfully replace the benzoate ring
of C646 and still retain p300 inhibitory
potency. Interestingly, carbonyl substitu-
tion of the exomethylene vinyl (6q) shows
6-fold weaker potency compared with
C646.
Effects of C646 on Histone
Acetylation in Mouse Cells
We next investigated the effects of
compound C646 on cellular histone acet-
ylation using C3H 10T1/2 mouse fibro-
blasts. We examined histone acetylation
using modification-specific antibodies
against H3K9ac and H4K12ac (Figure 5).
In addition to analysis of total acetylation
levels by western blots of SDS gels
(Figure 5A) we used acid-urea (AU) gels
(Figure 5B) which separate histones
on the basis of charge. Loss of a positive
charge upon lysine acetylation retards
migration, producing a ladder of bands
corresponding to integral changes in
acetylation (Shechter et al., 2007).
In control cells, basal acetylation levels
of H3 and H4 are slightly diminished by
C646 treatment over the 1-3 hr time-course tested (Figures 5A and 5B; lanes 1-4). To further investi-
gate this effect, we used a 30 min treatment with the HDAC inhib-
itor trichostatin A (TSA; Yoshida et al., 1990), which produces
increased H3 and H4 acetylation, visualized by the appearance
of higher migrating forms in AU gels (Figures 5A and 5B;
compare lanes 1 and 5). At all time points tested (1-3 hr; lanes
6-8), incubation with 25 mM C646 prior to addition of TSA virtually
completely inhibits this inducible acetylation, both in SDS
and AU gels.
By contrast 3 hr treatment with the C646 analog C37, which is
devoid of p300 HAT inhibitory activity in vitro, produces no effect
on acetylation of H3 or H4 (Figures 5A and 5B; lanes 9, 10). Thus,
blockade of p300/CBP by C646 treatment of intact cells results
in inhibition of both basal and TSA-inducible acetylation of
histones H3 and H4, demonstrating its efficacy in live cells.ª2010 Elsevier Ltd All rights reserved 475
Figure 5. C646 Treatment Reduces Histone
H3 and H4 Acetylation Levels and Abro-
gates TSA-Induced Acetylation in Cells
Quiescent C3H 10T1/2 mouse fibroblasts were
pretreated with C646 (25 mM, lanes 2-4, 6-8) for
the indicated times (1, 2, or 3 hr) or the control
compound, C37 (25 mM, 3 hr, lanes 9, 10), and
TSA (33 nM) added where indicated (lanes 6-8,
10) for the final 30 min of incubation. Histones
were extracted and analyzed by western blotting
to visualize total H3 and H3K9ac using SDS (A)
or H3, H3K9ac, and H4K12ac using acid-urea (B)
gel electrophoresis. Acid-urea gels separate
histones on the basis of charge. Each acetylation
event incrementally retards migration to produce
a ‘‘ladder’’ of bands, numbers on either side of
the blot indicating extent of modification (lane 1,
untreated control cells; lane 5, TSA-treated cells).
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p300/CBP HAT InhibitionSimilar inhibition was observed in cells subject to RNA interfer-
ence targeting this enzyme (N.T.C., C.A.H., E.M.B., R.M.A.,
and L.M., unpublished data).
Cell Growth Effects of C646 on Melanoma
and Lung Cancer Lines
Given the broad and important effects of p300/CBP on key
genes and pathways involved in cell growth, we explored the
pharmacologic effects of C646 on 3H-thymidine incorporation
at 24 hr in three melanoma (Figure 6A) and three non-small-cell
lung cancer lines (Figure 6B). We compared the effects of
C646 (10 mM) and the peptide-based bisubstrate p300/CBP
HAT inhibitor Lys-CoA-Tat (25 mM) and found that both were
capable of reducing 3H-thymidine incorporation in several of
these human cancer lines to varying degrees (Figures 6A and
6B). Control compounds, C37 and Ac-DDDD-Tat, which lack
p300 inhibitory properties, had no effects on 3H-thymidine incor-
poration as shown in Figures 6A and 6B. In general, reduction
of 3H-thymidine incorporation was correlated for Lys-CoA-Tat
and C646 among the different cell lines (Figures 6A and 6B),
consistent with a common protein target presumed to be
the p300/CBP HAT, although C646 generally showed greater
effects at the doses used. For example, the melanoma line
WM35 and the lung cancer line H23 were quite susceptible to
C646 treatment, with Lys-CoA-Tat, showing modest inhibitory
effects in these cells. Notably, the immortalized murine fibroblast476 Chemistry & Biology 17, 471–482, May 28, 2010 ª2010 Elsevier Ltd All rights reservedcell line, NIH 3T3, was not inhibited by
C646 at 20 mM, suggesting a differential
effect on the malignant cells evaluated
(Figure 6C).
We pursued more detailed studies on
the moderately sensitive melanoma line
WM983A and showed that the IC50 for
C646 was in the range of 10-20 mM, but
that this cell line was resistant to the
C646 analog control compound C37 at
20 mM (Figure 7A). Correlating with this
growth effect on WM983A cells was
a dose-dependent reduction in global
histone H3 acetylation revealed bywestern blotting that were treated for 6 hr (Figure 7B). Based on
fluorescence-activated cell sorting (FACS) analysis, the effects
of C646 (20 mM, 24 hr treatment) on WM983A and the more sensi-
tive melanoma line WM35 were consistent with a G1-S cell cycle
arrest, predicted to be related to p300 modulation (Iyer et al.,
2007), because the S-phase dropped under these conditions
(Figure 7C).
DISCUSSION
This study has led to the identification of a relatively potent and
selective small molecule p300 HAT inhibitor, which was discov-
ered by using virtual ligand screening. The docking model used
the ICM approach, which has been successful in identifying
ligands for a range of other protein targets (Szewczuk et al.,
2007; Mallya et al., 2007; Bisson et al., 2009; Cavasotto et al.,
2008). An X-ray crystal structure of the complex of p300 HAT
with the bisubstrate analog Lys-CoA revealed a pocket that
included a series of hydrogen bonding residues that interact
with the pantetheine moiety of Lys-CoA as well as two phos-
phate groups. The pyrazolone C646 was predicted to dock
into this site, utilizing several of the same residues. Such active
site interactions between C646 and p300 were projected to
result in exclusion of acetyl-CoA. Consistent with this model,
C646 was a competitive p300 inhibitor versus acetyl-CoA using
steady-state kinetic analysis. No evidence of time-dependent
Figure 6. p300/CBP HAT Inhibitors and Cell Growth Effects
(A) C646 has a more potent effect on cell growth than Lys-CoA-Tat does. Cells were treated for 24 hr and proliferation was measured via 3H-thymidine incorpo-
ration pre- and posttreatment. Data for each cell line were normalized to 3H counts measured pretreatment. C37 is an inactive derivative of C646. DMSO serves as
a vehicle control for C37 and C646. Ac-DDDD-Tat is a control peptide for Lys-CoA-Tat. WM35, WM983A, and 1205Lu are melanoma cell lines representing three
stages of cancer progression: radial, vertical, and metastatic, respectively.
(B) Two out of three non-small-cell lung adenocarcinoma cell lines demonstrate significant growth inhibition after treating with C646 and Lys-CoA-Tat for 24 hr.
(C) C646 does not have a significant inhibitory effect on NIH 3T3 cell proliferation.
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p300/CBP HAT Inhibitioninactivation of p300 by C646 was observed, arguing against the
idea that C646 was undergoing covalent reaction with the
enzyme. For an ordered binding mechanism like p300s, bisub-
strate analogs are predicted to be noncompetitive inhibitors
versus the second substrate, as found for C646.
The nature of the interaction between C646 and p300 was also
probed by altering enzyme residues and functional groups in the
inhibitor. These studies showed a maximal effect of a 7-fold
drop in affinity by mutagenesis of Trp1466 to Phe in p300 and
> 15-fold effects for several synthetic modifications of C646.
Taken together, these results further support active site targeting
of p300 by C646, although ultimately an X-ray crystal structure of
the complex will be needed to most rigorously test the computa-Chemistry & Biology 17,tional model proposed. The relative resistance of the W1466F
p300 mutant to C646 but the retention of wild-type catalytic
activity suggest that it may ultimately be possible to pursue
chemical-genetic complementation studies on p300/CBP analo-
gous to those done on protein kinases (Shogren-Knaak et al.,
2001; Qiao et al., 2006).
Compound C646 appears selective versus the other acetyl-
transferases so far examined. Compared with HDACS, HATs
show greater sequence and structural divergence and specific
targeting is more tractable (Hodawadekar and Marmorstein,
2007; Haberland et al., 2009; Cole, 2008). Although p300 and
Rtt109 are similar in fold, these two proteins show very little or
no sequence homology to other HATs and very modest471–482, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 477
Figure 7. C646 Inhibits Histone Acetylation
in Melanoma and Confers G1-S Phase Cell
Cycle Blockade
(A) C646 inhibits WM983A melanoma cell prolifer-
ation but C37 does not. Cells were treated with
each compound for 24 hr. Proliferation was mea-
sured via 3H-thymidine incorporation.
(B) C646 blocks H3 acetylation in WM983A cells.
Cells were treated for 6 hr with increasing concen-
trations of C646. Nuclear lysates were subjected
to western blot analysis for acetylated H3 (Upstate
06-599). Total H3 (Abcam ab1791) was blotted as
a loading control.
(C) C646 causes growth arrest in melanoma cell
line WM35 and WM983A, indicated by a decrease
in %S phase. Cells were treated for 24 hr with
20 mM C646 or DMSO, then collected and stained
with propidium iodide, followed by FACS analysis.
Chemistry & Biology
p300/CBP HAT Inhibitionstructural detailed homology in active-site interactions (Wang
et al., 2008). Moreover, the GNATs PCAF and serotonin N-ace-
tyltransferase and the MYST family member MOZ make distinc-
tive three-dimensional interactions with CoA (Hodawadekar and
Marmorstein, 2007).
The most potent and selective small molecule p300/CBP HAT
inhibitor prior to this study is a garcinol derivative, LTK14, with
a Ki of 5.1 mM (Mantelingu et al., 2007; Arif et al., 2009), about
12-fold weaker than C646. The complex natural product analog
LTK14 is suggested to be a noncompetitive p300 inhibitor versus
both acetyl-CoA and peptide and the structural basis of inhibi-
tion remains uncertain (Arif et al., 2009). Other published, small
molecule p300 inhibitors including anacardic acid, curcumin,
plumbagin, and isothiazolones have been demonstrated to be478 Chemistry & Biology 17, 471–482, May 28, 2010 ª2010 Elsevier Ltd All rights reservednonspecific or are predicted to be quite
chemically reactive, limiting their utility
(Stimson et al., 2005; Balasubramanyam
et al., 2003; Balasubramanyam et al.,
2004; Ravindra et al., 2009). Lys-CoA is
20-fold more potent than C646 but is
not cell permeable. Lys-CoA-Tat is more
potent in vitro than C646 but is apparently
also less active in cells and is a much
more complicated molecule to make
and work with.
Virtual ligand screening offers a rela-
tively rapid, economical approach to
search for potent enzyme inhibitors. The
complexity of coping with solvation and
conformational changes in proteins and
estimating energetics of atomic interac-
tions makes small molecule in silico
docking a continuing challenge. Indeed,
only three of the top 194 computational
p300 ligands were confirmed to be
reasonably potent inhibitors and only
one proved competitive versus acetyl-
CoA as predicted. It is generally under-
stood that the virtual screening againstone of even several conformations of the binding pocket is
not designed to identify all potential p300/CBP inhibitors
because the conformations of the binding pocket for certain
chemical classes of inhibitors may extend far beyond the
pocket conformation we used. Nevertheless, we suspect that
even identifying one relatively potent and selective active site
compound for p300 out of 194 experimentally tested com-
pounds represents a higher ratio of success than expected
from a high-throughput screen of unselected small molecule
libraries (Stimson et al., 2005).
We have also shown that C646 works rapidly in cell culture in
blocking histone acetylation. The application of selective
p300/CBP HAT inhibitors in vivo can help address a range of bio-
logical and pathophysiologic questions.
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HDAC inhibitors, despite their limited selectivity, have been
enormously important in dissecting the role of histone acet-
ylation in gene expression pathways, and SAHA is clinically
used for cancer treatment (Itoh et al., 2008). Our data here
with the relatively potent, selective p300/CBP inhibitor C646
indicate the potential of p300/CBP HAT blockade in imped-
ing cancer proliferation, though more work will be needed
to clarify themultiple potential mechanisms for such growth
effects. Other recently published studies underscore the
potential value of blocking p300/CBP HAT in the treatment
of diabetes mellitus, cardiac disease, and HIV (Cole 2008).
EXPERIMENTAL PROCEDURES
Molecular Modeling
The crystal structure of p300 HAT in complex with bisubstrate analog Lys-CoA
(Protein Data Bank ID 3BIY) was prepared for virtual screening using the
Internal Coordinate Mechanics (ICM-Pro) software version 3.5 (MolSoft LLC,
San Diego CA) (Abagyan et al., 1994). The ligand and heteroatom molecules
were removed from the structure and a continuous dielectric was used in place
of the water molecules. Missing hydrogen and heavy atoms were added and
atom types and partial charges were assigned. The protein model was
adjusted so that the optimal positions of polar hydrogens were identified,
the most isomeric form of each histidine was assigned and the correct orien-
tation of the side-chains of glutamine and asparagine were found. Steric
clashes were removed by an energy minimization procedure.
Virtual Screening
Virtual screening was undertaken with the ICM-VLS software version 3.5 (Mol-
Soft LLC, San Diego, CA) using dockScan version 4.4. This method uses an
extension of the Empirical Conformational Energy Program for Peptides 3
(ECEPP/3) (Nemethy et al., 1992) force field parameters for proteins and the
Merck Molecular Force Field (MMFF) (Halgren and Nachbar, 1996) for small
molecules. Five continuously differentiable potential grid maps were calcu-
lated for the receptor using spline interpolation for efficient gradient minimiza-
tion (Totrov and Abagyan, 1997). These maps include energy terms for electro-
statics, directional hydrogen bond, hydrophobic interactions, and two for van
der Waals interactions for steric repulsion and dispersion attraction including
a soft potential to limit the effect of minor steric clashes. A collection of
492,793 compounds from the ChemBridge small molecule database (Chem-
Bridge Corp, San Diego, CA) was screened to the p300 HAT bisubstrate inhib-
itor binding site. Each ligand was docked into the binding pocket three times.
During docking the ligand is flexible and its position and internal torsions are
sampled using the ICM biased probability Monte Carlo procedure, which
includes a local minimization after each random move. Each docked ligand
is assigned a score according to the weighted components of the ICM-VLS
scoring function (Totrov and Abagyan, 1999).
Peptide Synthesis
Synthetic peptides (H4-15, p300 peptides, Lys-CoA-Tat, Ac-DDDD-Tat) were
prepared using automated solid phase peptide synthesis and the Fmoc
strategy as described previously (Thompson et al., 2001; Zheng et al., 2005;
Guidez et al., 2005; Liu et al., 2008a, 2008b). Peptides were purified using
reverse-phase HPLC and their structures confirmed by mass spectrometry.
Purification of Semisynthetic p300 HAT Domain
A variant of the HAT domain of p300 (residues 1287 to 1652) was expressed as
a fusion with the VMA intein chitin binding domain as described previously
(Thompson et al., 2004). Residues 1529-1560, comprising the regulatory
autoacetylation loop, were deleted in the construct, rendering the enzyme
constitutively active. The construct also contained an M1652G mutation.
E. coli BL21(RIL)-DE3 cells containing the construct were grown to OD600 of
0.6 at 37C. The incubator was cooled to 16C, and expression was induced
by addition of 500 mM IPTG. Following overnight expression, the cells wereChemistry & Biology 17,centrifuged and resuspended in lysis buffer prior to lysis via three passes
through a French pressure cell. Lysates were clarified through centrifugation
and incubated with chitin resin for 30 min at 4C. The resin was washed thor-
oughly before addition of 200 mM MESNA and a C-terminal peptide corre-
sponding to residues 1653-1666 of p300. The expressed protein ligation reac-
tion was allowed to proceed for 16 hr followed by purification over a MonoS
5/50 GL strong cation exchange column (GE Healthcare) using linear gradients
of NaCl (50 to 1000 mM). Purified semisynthetic p300 was concentrated and
dialyzed against 20 mM HEPES (pH 7.9), 50 mM NaCl, 1 mM DTT, and 10%
glycerol (v/v) prior to flash-freezing in liquid N2 and storage at 80C. Protein
concentration was determined by gel and by Bradford assay using bovine
serum albumin (BSA) as a standard.
Initial Screen of VLS Hits
The top 194 p300 HAT inhibitor candidates identified by VLS were screened
using a coupled spectrophotometric assay. In this assay, CoASH produced
by the p300 reaction is used by a-ketoglutarate dehydrogenase (a-KGDH) to
produce NADH, which can be monitored spectrophotometrically at 340 nm
(Kim et al., 2000). Reactions were performed at 30C in 1 M HEPES (pH 7.9)
and contained 200 mM H4-15, 200 mM TPP, 5 mM MgCl2, 1 mM DTT, 50 mg/mL
BSA, 200 mM NAD, 2.4 mM a-ketoglutarate, 200 mM acetyl-CoA, 0.1 units
a-KGDH, and 100 nM p300. DMSO was kept at a constant 3.3%, and candi-
date compounds were screened at 100 mM. Reaction mixtures were incubated
at 30C for 10 min prior to initiation. Reactions were initiated with addition of
H4-15 and followed over the linear portion of the progress curve, which
provides the initial velocity via linear regression. Percent inhibition was deter-
mined by comparison with velocity without candidate added. Compounds
that exhibited over 40% inhibition were subjected to further screening steps.
To ensure that compounds were not inhibiting a-KGDH instead of p300,
compounds were assayed with 0.2 units of a-KGDH, two times the amount
used in the initial screen. To ensure that compounds were not inhibiting
through nonspecific aggregation, compounds were assayed in the presence
of 0.01% Triton X-100. Compounds whose inhibition was greatly decreased
either by raising the a-KGDH concentration or by preventing nonspecific
aggregation were removed from further consideration.
Compounds that passed the iterative verification process in the initial screen
were then tested in a direct radioactive assay. In this assay, production of
14C-labeled Ac-H4-15 is monitored electrophoretically (Thompson et al.,
2001). Reactions were performed in 20 mM HEPES (pH 7.9), and contained
5 mM DTT, 80 mM EDTA, 40 mg/ml BSA, 100 mM H4-15, and 5 nM p300.
DMSO was kept constant at 2.5%, and inhibitors were screened at 25 mM.
Reactions were incubated at 30C for 10 min, initiated with addition of a 1:1
mixture of 12C-acetyl-CoA and 14C-acetyl-CoA to a final concentration of
20 mM, and allowed to run for 10 min at 30C. Reactions are then quenched
with addition of 14% SDS (w/v). Turnover was kept below 10%. All compounds
were screened in duplicate. Samples were then loaded onto a 16% Tris-Tricine
gel along with a BSA standard and run at 140 V for 90 min. Gels were washed
and dried, and exposed in a PhosphorImager cassette for2 days. Bands cor-
responding to Ac-H4-15 were then quantified using ImageQuant. Compounds
exhibiting over 40% inhibition compared to control were then kinetically
characterized.
Kinetic Characterization of Verified Inhibitors and Analogs
IC50 values for the putative p300 HAT inhibitors identified through the initial
screen were determined using the direct radioactive assay described above.
Reactions were performed in 20 mM HEPES (pH 7.9), and contained 5 mM
DTT, 80 mM EDTA, 40 mg/ml BSA, 100 mM H4-15, and 5 nM p300. Putative
inhibitors were added over a range of concentrations, with DMSO concentra-
tion kept constant (<5%). Reactions were incubated at 30 for 10 min, then
initiated with addition of a 1:1 mixture of 12C-acetyl-CoA and 14C-acetyl-
CoA to 20 mM. After 10 min at 30C, reactions were quenched with 14%
SDS (w/v). All concentrations were screened in duplicate. Gels were run,
washed, dried, and exposed to a PhosphorImager plate as described above,
and production of Ac-H4-15 quantified to obtain IC50s.
Patterns of inhibition of putative p300 HAT inhibitors were determined in
a similar fashion. One substrate was held constant while the other was varied
over a range of three inhibitor concentrations (0, 0.5 3 IC50, and IC50). AcCoA
was varied from 5-120 mM while holding H4-15 constant at 100 mM, and H4-15471–482, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 479
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Reactions were performed in duplicate as described above; enzyme concen-
tration and reaction time were varied to keep turnover below 10%. Following
quantification, data were globally fit to equations for competitive or noncom-
petitive inhibition to determine the optimal pattern of inhibition (Copeland,
2000).
Determining Inhibitor Specificity for p300 HAT
C646, C375, and C146 were screened spectrophotometrically against PCAF
(p300/CBP-associated factor, a histone acetyltransferase) and AANAT (arylal-
kylamine N-acetyltransferase, a non-histone acetyltransferase) using a similar
coupled assay as described above. PCAF reactions were performed in
100 mM HEPES (pH 7.9), and contained 200 mM TPP, 5 mM MgCl2, 1 mM
DTT, 50 mM NaCl, 0.05 mg/ml BSA, 200 mM NAD, 2.4 mM a-KG, 30 mM
acetyl-CoA, 0.037 units a-KGDH, 3.3% DMSO, and 10 mM inhibitor. Reactions
took place at 30C. Reactions were initiated by addition of 10 nM PCAF and
were followed at 340 nm over the linear portion of the curve below 10% turn-
over. AANAT reactions were performed in 100 mM NH4OAc (pH 6.8) and con-
tained 200 mM TPP, 5 mM MgCl2, 1 mM DTT, 50 mM NaCl, 0.05 mg/ml BSA,
200 mM NAD, 2.4 mM a-KG, 200 mM AcCoA, 0.1 units a-KGDH, 3.3% DMSO,
and 10 mM inhibitor. Reactions took place at 25C. Reactions were initiated
with addition of 65 nM AANAT, and followed at 340 nm, as above. Percent inhi-
bition values were compared to those with p300, which were repeated using
the protocol given above. C646 was further analyzed as a potential HAT inhib-
itor with yeast GCN5, the Sas2/4/5 complex, MOZ, and Rtt109. Yeast GCN5,
MOZ, and the Rtt109/Vps75 complex were purified as described elsewhere
(Poux et al., 2002; Tang et al., 2008; Holbert et al., 2007). The SAS complex
was expressed and purified in E. coli as detailed elsewhere (Shia et al.,
2005; Sutton et al., 2003). Briefly, the SAS2, SAS4, and SAS5 proteins were
coexpressed using the Duet system (Novagen) in BL21-CodonPlus(DE3)-RIL
cells (Strategene). The complex was purified using a combination of nickel
affinity, ion exchange (HisTrap SP), and gel filtration (Superdex 200) chroma-
tography.
HAT assays with yeast GCN5, SAS complex, MOZ, and Rtt109/Vps75
complex used the direct radioactive assay described above. Reactions were
carried out at 30C for times varying from 2 to 4 min under the following reac-
tion conditions: 50 mM HEPES (pH 7.9), 50 mM NaCl, 0.05 mg/ml BSA, 5 mM
DTT, 0.05 mM EDTA, 0.25% DMSO, 10 mM X. laevis histone H3, and varying
concentrations of C646 (0, 3, 10 mM). The reactions contained either 70 ng
Rtt109/Vps75, 15 ng yGcn5, 300 ng SAS complex, or 1 mg hMOZ. The amount
of enzyme used in each assay was estimated by comparing Coomassie blue
staining of samples with BSA standards, analyzed by SDS-PAGE. The mixture
was allowed to equilibrate at 30C for 10 min before the reaction was initialed
with addition of a 1:1 mixture of 12C-AcCoA and 14C-AcCoA to a final con-
centration of 20 mM. After the appropriate time the reaction was quenched
with 6 X Tris-Tricine gel loading buffer, which contained 0.2 M Tris-Cl
(pH 6.8), 40% v/v glycerol, 14% w/v SDS, 0.3 M DTT, and 0.06% w/v Coomas-
sie blue. The 14C-labeled histone substrates were separated from reactants
on a 16.5% Tris-Tricine SDS-PAGE gel. The rate of 14C-incorporation into
histone H3 was quantified by autoradiography. We performed all assays in
duplicate, and these generally agreed within 20%.
Time Course Studies
Time courses of p300 HAT with C646 were determined using the radioactive
assay described above. Reactions were performed using the conditions
detailed above with 1.5 mM C646. Reactions were quenched at particular
time intervals, then run on a 16% Tris-Tricine gel and quantified as described
above. Similar studies were performed varying the time of p300 HAT pre-incu-
bation with C646. Assays contained the conditions detailed above, with 1.5 mM
C646 added at various times prior to initiation with 10 mM acetyl-CoA. Reac-
tions were quenched after 5 min, then run on a 16% Tris-Tricine gel and quan-
tified as described above. All time points were screened in duplicate.
Inhibition with p300 Mutants
Sites for mutation were chosen by examination of the C646 binding model
generated during VLS. T1411A, W1466F, Y1467F, and R1410A mutations
were installed using QuikChange protocols. p300 variants were expressed in
E. coli BL21(RIL)-DE3 cells and purified using expressed protein ligation as480 Chemistry & Biology 17, 471–482, May 28, 2010 ª2010 Elsevierdescribed above. IC50 values for C646 with all mutants were obtained using
the methods described above. All assays contained 10 mM of a 1:1 mixture
of 12C-acetyl-CoA and 14C-acetyl-CoA and 400 mM H4-15. Reaction time
was varied between 5 and 10 min to keep turnover below 10%. Enzyme
concentrations were altered for each mutant, as active site mutations affected
enzyme activity. In a similar fashion, kinetic parameters for each mutant versus
AcCoA were determined. [H4-15] was 400 mM, and DMSO was held constant
at 2.5%. Reactions proceeded for 6 min before being quenched and run on
a 16% Tris-Tricine gel as described above. Data were quantified and fit to
the Michaelis-Menten equation.
NMR Studies
The 2D 1H-1H correlation spectra were acquired at 30C on an 11.7 T Varian
INOVA spectrometer using a pentaprobe equipped with z-axis pulse-field
gradient coils.
Data were processed and analyzed using NMRPipe (Delaglio et al., 1995).
The sample contained 600 ml 10 mM C646 DMSO-d6 solution.
Histone acetylation assays in mouse cells
C3H 10T1/2 mouse fibroblasts were grown in DMEM with 10% FCS at 37C
with 6% CO2.
Confluent cultures were rendered quiescent in DMEM with 0.5% FCS for
18-20 hr prior to treatment. Cells were treated with the following compounds:
TSA (10 ng/ml [33 nM]; Sigma), C646 (25 mM), C37 (25 mM). Antibodies were
used at the following concentrations: total H3 (1:10000; ab7834; Abcam);
H4K12ac (1:2500; 06-761; Upstate). Rabbit anti-H3K9ac (1:10000) antibodies
were generated in-house (Edmunds et al., 2008). Histones were isolated from
cells by acid extraction, separated by SDS and acid-urea polyacrylamide gel
electrophoresis and analyzed by western blotting as described previously
(Thomson et al., 1999; Clayton et al., 2000).
Cancer Cell Studies
Melanoma cell lines WM35, WM983A, and 1205Lu were generous gifts from
Meenhard Herlyn’s lab at the Wistar Institute (Philadelphia, PA). Non-small-
cell lung cancer (NSCLC) cell lines H23 and H838 were obtained from
Dr. Charles Rudin’s lab, and H1395 from Dr. Craig Peacock’s lab, at Johns
Hopkins. Melanoma cells were maintained in Dulbecco’s modified Eagle
medium. NSCLCs were maintained in RPMI Medium 1640. Both types of
media were supplemented with 10% fetal bovine serum (FBS), penicillin-strep-
tomycin, and L-glutamine. Media, pen-strep, and L-glutamine were purchased
from Invitrogen. FBS was purchased from Gemini Bio-Products (#100106).
Before treating cells with p300 inhibitors (C646, Lys-CoA-Tat [Zheng et al.,
2005; Guidez et al., 2005]) or control compounds (C37, Ac-Asp-Asp-Asp-
Asp-Tat [also known as Ac-DDDD-Tat]), cells were plated at sub-confluent
concentration (60%) and incubated at 37C until attached to the plating
surface. Compound stocks (10-20 mM in anhydrous DMSO) were directly
added to culture media at desired concentrations. DMSO concentration was
kept constant at 0.2% between different treatment conditions. Cells were
seeded in 96-well plates at 5000 cells per well on average, depending on
each cell line’s doubling time. After attachment, cells were treated with p300
inhibitors, control compounds, or DMSO for 24 hr. After treatment, 3H-thymi-
dine (1 mCi/ml stock) was added to media at 10 mCi/ml final concentration.
Cells were incubated for an additional 5 hr, then trypsinized and collected
onto a filter mat using a Cell Harvester (PerkinElmer). Radioactivity was
measured with a MicroBeta plate reader (PerkinElmer). Each sample was
tested in triplicate.
Cell Cycle Analysis
Cells treated with C646 or DMSO were stained with propidium iodide (PI)
according to a published protocol (Robinson, 2009). Briefly, equal numbers
of cells (greater than 106) in 0.5 ml phosphate-buffered saline (PBS) were fixed
in 70% ethanol for at least 2 hr at 4C. A stock staining solution containing
10 ml 0.1% Triton X-100 in PBS, 400 ml of RNase cocktail (equivalent of
200 units of RNase A) (Ambion), and 200 ml of 1 mg/ml PI was prepared. Fixed
cells were spun at 200 g for 5 min (Beckman Coulter Allegra X-12R, with an
SX4750A rotor), rehydrated in 5 ml PBS, and spun again to remove all traces of
ethanol. Cells were stained with 1 ml staining solution for 20 min at 37C, then
immediately analyzed on a FACSCalibur flow cytometer (BD Biosciences) atLtd All rights reserved
Chemistry & Biology
p300/CBP HAT Inhibitionthe Johns Hopkins Flow Cytometry Core Facility. Data acquisition and analysis
were performed with the CellQuest software (BD). WinMDI 2.9 (http://facs.
scripps.edu.software.html) was also used for data presentation.SUPPLEMENTAL INFORMATION
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